You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

SYSTEMATIC REVIEW article

Front. Pediatr., 28 July 2023

Sec. Pediatric Neurology

Volume 11 - 2023 | https://doi.org/10.3389/fped.2023.1189648

Prevalence and related factors of epilepsy in children and adolescents with cerebral palsy: a systematic review and meta-analysis

  • 1. College of Rehabilitation Medicine, Jiamusi University, Jiamusi, China

  • 2. Jiamusi University Affiliated No.3 Hospital, Jiamusi, China

  • 3. School of Science, Faculty of Engineering and Science, University of Greenwich, Medway Campus Central Avenue, Chatham Maritime, Kent, England

Article metrics

View details

19

Citations

9,4k

Views

2,7k

Downloads

Abstract

Objective:

To study the worldwide prevalence and associated factors of epilepsy in children and adolescents with Cerebral Palsy (CP) and to analyze the differences between various subgroups.

Method:

We identified all potential studies on the prevalence of epilepsy in children and adolescents with CP from PubMed, Web of Science, and Embase. The search time was from the establishment of the database to November 2022. Randomized effects meta-analysis models were used to calculate the prevalence of epilepsy in CP. Subgroup analysis and meta-regression were utilized to further explore heterogeneity between articles and prevalence disparities between subgroups. The funnel plot and Egger's test were used to investigate potential publication bias.

Results:

Seventy-two articles, comprising 53,969 children and adolescents with CP, were included in this study. The results indicated a total epilepsy prevalence of 38.0% (95% CI: 34.8%–41.2%) in CP. The prevalence of epilepsy was 46.4% (95% CI: 41.4%–51.5%) in clinical sample-based studies and 31.6% (95% CI: 28.7%–34.5%) in population-based studies. Meta-regression demonstrated that the sample source, neonatal seizure, family history of epilepsy, EEG or cranial imaging abnormalities, intellectual/cognitive impairment, and topographical types of CP were heterogeneous contributors to the epilepsy prevalence in CP.

Conclusion:

Approximately one-third of children and adolescents with CP have epilepsy, and the sample source can significantly impact the total prevalence of epilepsy. Neonatal seizures, family history of epilepsy, EEG abnormalities, cranial imaging abnormalities, severe intellectual disability, and quadriplegia may be contributing factors to epilepsy comorbid in CP. Further study is required to verify the strength of these associations with epilepsy. This study aids in identifying the clinical characteristics of young people with CP at risk of developing epilepsy, which may assist clinicians in the early prevention and diagnosis of epilepsy within this population.

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=367766, identifier CRD42022367766.

1. Introduction

Cerebral palsy (CP) is a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain (1). The motor disorders of CP are often accompanied by disturbances of sensation, perception, cognition, communication, behaviour, epilepsy, and secondary musculoskeletal problems (1). According to population-based studies, the global prevalence of CP ranges between 0.1% and 0.4% (2), making it a common disorder threatening the early survival of children.

Epilepsy is an independent, significant, and common clinical problem in children with CP and is often regarded as an indicator of CP severity. The prevalence of epilepsy in the general population ranges from 0.4% to 0.8% (3). However it is significantly more prevalent in children with CP. Literature on epilepsy incidence in children with CP varies from 15% to 90%, with most estimates falling between 35% and 41%, making it five times higher than that of able-bodied children (4). This discrepancy may be attributed to CP and epilepsy sharing physiopathologic mechanisms caused by common etiology and risk factors. Many prenatal, peripartum, and postpartum injury, such as hypoxic-ischemic encephalopathy, infection, and congenital brain malformations, can cause CP and epilepsy (5). Epilepsy can be severe in some young people with CP, or it may be self-limiting and similar to other childhood epilepsies (6, 7). Nevertheless, epilepsy poses a significant threat to the early survival of young people with CP due to a variety of injuries and dysfunctions. The onset of epilepsy often indicates a more severe brain injury, affecting all functional aspects (8). Studies have shown that CP with epilepsy are often associated with severe intellectual disabilities, movement disorders, psychological and behavioral problems, and a lower quality of life, with less autonomy (9).

Many studies have shown that CP and epilepsy share a common etiologies and risk factors, and their co-occurrence rate is high. However, no systematic review and meta-analysis have yet been conducted on the prevalence of epilepsy in CP. Therefore, this systematic review aims to retrieve all published articles on the prevalence of epilepsy in children and adolescents with CP, estimate the epilepsy prevalence in CP using a meta-analysis, and analyze factors leading to epilepsy in CP, to provide evidence-based medical support.

2. Method

The protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) (registration number: CRD42022367766).

2.1. Search strategy

Three databases (PubMed, Embase, and Web of Science) were systematically searched to determine the prevalence of epilepsy in children and adolescents with CP for all potentially relevant studies from database establishment to November 2022. The following search terms were used: cerebral pals*, CP, Little Disease, Spastic Diplegia, epileps*, seizure*, Aura, Convulsion, prevalence, epidemic, epidemiology, rate, morbidity, searched by combining MeSH Terms and Title/Abstract, combined according to Boolean logic principles (using AND, OR, or NOT). We used Endnote 20 to manage and remove repetitive articles. The reference lists of selected articles were also manually searched. In addition, articles on either CP or the prevalence of comorbidities with CP were searched in this systematic review. The search terms were presented in Supplementary S1.

2.2. Inclusion and exclusion criteria

2.2.1. Inclusion criteria

(1) Articles that directly or indirectly reported the prevalence of CP with epilepsy. (2) English articles. (3) Articles containing original data: a cross-sectional study, a case-control study, and a cohort study. (4) Children and adolescents under the age of 19 with CP were included, in line with World Health Organization (WHO) criteria for the age of children and adolescents (10).

2.2.2. Exclusion criteria

(1) Reviews, systematic reviews, meta-analyses, meeting summaries, student papers, comments, or letters. (2) To ensure that estimates reflect the expected population, articles with fewer than 50 participants were excluded. (3) The full text could not be obtained. (4) Article data were missing, repeated, or unavailable. (5) Articles on studying a certain type of CP population.

2.3. Article selection and data extraction

Two reviewers (CG and BBL) screened the retrieved articles by reading titles and abstracts according to the above criteria to exclude unrelated and repetitive articles, then read the full texts of the remaining publications independently. Finally, they discussed differences with a third expert (JG) to reach a consensus. The following data were extracted separately from each article: first author, year of publication, time of case collection, type of study, the total number of individuals with CP, number with epilepsy, prevalence, age, diagnostic criteria for epilepsy developed by the International League Against Epilepsy (ILAE), and proportion of females. If necessary, the study authors were contacted for more data or clarification. After discussion, the disagreement was resolved by consensus with the third senior reviewer (ZMJ).

2.4. Quality assessment

We used the Hoy et al. (11) tool to assess the risk of bias in studies measuring the prevalence of epilepsy in CP. The tool included ten items to judge the risk of bias: (1) selection-related bias, (2) bias associated with non-response, (3) measurement-related bias, and (4) bias associated with analysis. Each item included two options: (1) high or low risk. The high-risk option was chosen if the study lacked basic information to make the judgment. The overall assessment of the risk of bias was rated as low (three or fewer high-risk items), moderate (four to five high-risk items), and high (six or more high-risk items) risk bias. Two reviewers (XXW and PZ) individually reviewed each study. The disagreement was resolved by consensus and in consultation with the senior reviewer (WP). The details of Hoy were presented in Supplementary S2.

2.5. Data synthesis and analysis

Stata 17.0 (Stata Corp, College Station, TX, USA) was used to analyze the prevalence of epilepsy in children and adolescents with CP and provided its 95% confidence interval (CI). The Q test analyzed the heterogeneity among the included studies, and I2 quantitatively judged the heterogeneity. If the heterogeneity was high (I2  ≥  50%), the source of heterogeneity was further analyzed. After excluding the influence of articles with obvious heterogeneity, the random effect model (REM) was used for Meta-analysis. Otherwise, the fixed effect model (FEM) was used. Subgroup analysis and Meta-regression analysis were used to explore the sources of heterogeneity and the differences in the prevalence of epilepsy among subgroups.

According to the sample source in the articles, we divided the articles into two groups: a clinical sample-based study group and a population-based study group. Clinical sample-based studies considered individuals with CP from hospitals, clinics, or rehabilitation institutions. Population-based studies were considered individuals with CP in the entire population or a random sampling population. Subgroup analysis was performed on the gender, ethnic group, study type, national income level, diagnostic criteria for epilepsy developed by the International League Against Epilepsy (ILAE), and publication time of the two groups to explore the sources of heterogeneity and the differences in the prevalence of epilepsy between different groups.

In addition, we performed subgroup analysis and meta-regression analysis based on the characteristics of children with CP to explore the differences in the prevalence of epilepsy between different groups. The related factors included gestational age, birth weight, birth asphyxia, neonatal seizures (NS), family history of epilepsy, central nervous system (CNS) abnormalities based on MRICS (Magnetic Resonance Imaging Classification System), electroencephalography (EEG) abnormalities, cranial imaging abnormalities, cognitive/intellectual status, clinical type of CP and topographical type of CP.

3. Results

3.1. Article selection

3,020 articles were retrieved: PubMed: 605, Embase: 904, Web of Science: 1,511. After removing duplicates, 1,641 articles remained. After title and abstract screening, 204 full-texts were evaluated for eligibility according to inclusion and exclusion criteria, 69 articles were included. In addition, 3 articles were included by other search methods. Therefore, a total of 72 articles were included in this study. The article selection process is shown in Figure 1.

Figure 1

Figure 1

Article screening process and result.

3.2. Article characteristic

The 72 articles included in this meta-analysis were published from 1998 to 2022, involving 38 countries and regions worldwide, and the data were collected from 1988 to 2019. There were 32 articles based on clinical samples and 40 articles based on population. According to the main ethnic composition of the country, the ethnic groups included are Europa (43 articles), Mongolian (8 articles), Black (11 articles), and multi-ethnic mixed (10 articles). The number of children with CP included in the article ranged from 62 to 9,654, totaling 53,969 people. The quality scores of the articles ranged from 1 to 5 points, of which 52 were low and 20 were moderate. A detailed description of the articles is shown in Table 1. The detailed quality assessment results are shown in Supplementary S3.

Table 1

First author Published time Countries or regions Main ethnic composition Time range of data collection CP Epilepsy Prevalence (%) Age (years), M (SD) Proportion of female (per 100) Diagnostic criteria of epilepsy Quality score
Come from clinical samples-based study
Kwong (12) 1998 China Mongolian ethnic group 1990–1995 85 32 37.6 2–17.5 43.5 ILAE in 1981,1989 and 1993 3
Zafeiriou (13) 1999 Greece European ethnic group – 493 178 36.1 – – ILAE in 1981,1989 and 1993 3
Bruck (14) 2001 Brazil Multi-ethnic group 1996–1998 100 62 62 2–18 49 ILAE in 1989 and 1993 3
Sianturi (15) 2002 Indonesia Mongolian ethnic group 1988.07–1998.06 67 25 37.3 0.5–14.5 52.2 ILAE in 1981 3
Şenbil (16) 2002 Turkey European ethnic group 1997–1999 74 31 41.8 2–10 41.8 ILAE in 1989 and 1993 3
Singhi (17) 2003 India European ethnic group – 452 160 35.3 1–14 – ILAE in 1981,1989 and 1993 3
Kulak (18) 2003 Poland European ethnic group 1994.10–2001.03 198 82 41.4 1–18 35.4 ILAE in 1989 4
Zelnik (19) 2011 Israel European ethnic group 2005–2006 197 65 32.9 7.2 (3.0); 1.4–12.8 40.6 ILAE in 1989 4
Mert (20) 2011 Turkey European ethnic group 2006.11–2009.10 98 56 57.1 3–16 42.8 ILAE in 1989 3
Frank-Briggs (21) 2011 Nigeria Black ethnic group 2008.06–2010.06 834 418 50.1 <10 35.73 – 3
Prasad (8) 2011 India European ethnic group 2007.09–2009.03 102 53 51.9 <15 23.5 – 4
Aronu (22) 2013 Nigeria Black ethnic group 2007.01.01–2009.12.31 164 62 37.8 – 43.9 ILAE in 1981 3
Kakooza-Mwesige (23) 2015 Uganda Black ethnic group 2009.09–2010.08 135 61 45.1 2–12 46.6 – 3
Keeratisiroj (24) 2015 Thailand Mongolian ethnic group 2008–2013 527 246 46.7 2–18 – – 3
Bearden (25) 2016 Botswana Black ethnic group 2013–2014 68 52 76.4 2–18 – – 4
Minocha (26) 2017 India European ethnic group 2012.3–2013.3 180 75 41.6 1–12 43.3 – 4
Gincota (27) 2018 Moldova European ethnic group 2016.6–2016.9 185 93 50.2 6.6–7.6 36.2 ILAE in 1993 3
Gürkan (28) 2018 Turkey European ethnic group 2008.01–2015.12 234 118 50.4 1–8.7 41 ILAE in 1993 4
Sucuoğlu (29) 2018 Turkey European ethnic group 2015.07–2017.08 204 66 32.3 10.35 (8.32) 42.2 – 4
Aydin (30) 2019 Turkey European ethnic group – 197 102 51.7 1–18 41.6 – 4
Karatoprak (31) 2019 Turkey European ethnic group 2002.12–2012.12 234 126 53.8 3–18 41.4 ILAE in 1981 3
Hanci (32) 2020 Turkey European ethnic group 2016.11–2019.11 229 120 52.4 1–13 44.9 ILAE in 2017 3
Pavone (33) 2020 Italy European ethnic group 2008.05–2018.11 93 46 49.4 1–10 52.5 – 4
Sadowska (34) 2020 Poland European ethnic group 2008–2016 181 102 56.3 4–17 45.8 – 3
Al-Blowi (35) 2020 Saudi arabia European ethnic group 2012–2016 119 95 79.8 1–12 52.9 – 5
Şik (36) 2021 Turkey European ethnic group 2012.01–2015.09 62 26 41.9 9.31 ± 4.13, 3–18 32.3 – 2
Tsige (37) 2021 Ethiopia Black ethnic group 2018.07–2018.09 174 106 60.9 2–18 – – 4
Jibril (38) 2021 Nigeria Black ethnic group 2018.09–2019.03 165 56 33.9 1–12 32.7 – 3
Chaudhary (39) 2022 Nepal Multi-ethnic group 2017.03–2018.03 110 73 66.3 0.5–15 25.4 ILAE in 2014 4
Mangamba (40) 2022 Cameroon Black ethnic group 2017.12.1–2018.5.31 198 68 34.3 0.25–15 45.9 ILAE in 2014 5
K, Archana (41) 2022 India European ethnic group 2018.01–2019.07 300 79 26.3 1–12 31 ILAE in 2017 4
Karim (42) 2022 Vietnam Mongolian ethnic group 2017.06–2017.11 765 82 10.8 <18 35.8 – 5
Comes from population-based study
Aneja (43) 2001 India European ethnic group – 831 121 14.5 – – ILAE in 1981 4
Nordmark (44) 2001 Sweden European ethnic group NA-1998 167 61 36.5 5–8 45.4 – 3
Parkes (45) 2001 Northern Ireland European ethnic group NA-2000.2 710 155 21.8 7–19 – – 3
Carlsson (46) 2003 Sweden European ethnic group 2000.11–2001.05 146 55 37.6 6–14 43.8 ILAE in 1981,1989 and 1993 4
El-Tallawy (47) 2007 Egypt European ethnic group – 98 48 48.9 – 46.9 ILAE in 1981 3
Beckung (48) 2007 Sweden European ethnic group – 176 62 35.2 5–8 – – 2
Andersen (49) 2008 Norway European ethnic group 2003.01.01–2006.03.31 294 80 27.2 1.9–10.2 49.3 ILAE in 1993 3
Sigurdardóttir (50) 2009 Iceland European ethnic group – 139 37 26.6 – 53.2 – 2
Kirby (51) 2011 The United States Multi-ethnic group NA-2006 476 166 34.8 8 45.4 ILAE in 1993 3
Himmelmann (52) 2011 Sweden European ethnic group – 186 82 44 4–8 48.3 ILAE in 1993 2
Sellier (53) 2012 European countries European ethnic group – 9,654 3,424 35.4 – 41.8 ILAE in 1993 4
Singhi (54) 2013 India European ethnic group 2000–2009 1,212 539 44.4 <8 38.9 – 3
Christensen (55) 2014 The United States Multi-ethnic group NA-2008 451 185 41 8 40 ILAE in 1993 3
Yalcinkaya (56) 2014 Turkey European ethnic group – 730 167 22.9 7.27 (4.63); 2–18 41.2 – 2
Granild-Jensen (57) 2015 Danish European ethnic group – 1,222 356 29.1 – 40.8 – 3
Meehan (58) 2015 Australia Multi-ethnic group 2008–2012 2,099 623 29.6 <19 – ILAE in 1993 2
Delacy (59) 2016 Australia Multi-ethnic group 2013 3,173 883 27.8 8–18 – ILAE in 1993 2
Tan (60) 2016 Netherlands European ethnic group 2002–2007 309 74 23.9 1–15 37.6 – 2
Khandaker (61) 2016 Bangladesh Multi-ethnic group 2015.01–2015.06 299 88 29.4 <18 – 1
Delobel-Ayoub (62) 2017 European countries European ethnic group – 1,225 374 30.5 0–19 – – 1
Abas (63) 2017 Egypt European ethnic group 2015.5–2015.11 200 76 38 0.25–18 45 – 1
Kakooza-Mwesige (64) 2017 Uganda Black ethnic group 2015.03.01–2015.6.30 360 77 21.3 2–17 – – 3
Yim (65) 2017 Korea Mongolian ethnic group NA-2015.01 773 243 30.3 – 42.8 – 3
Hollung (66) 2018 Norway European ethnic group 1999–2010 1,664 383 23 – – ILAE in 1993 1
Reid (67) 2018 Australia Multi-ethnic group – 1,005 299 29.7 – 41.7 ILAE in 1993 4
Chiang (68) 2019 Taiwan, China Mongolian ethnic group 2010–2011 8,419 2,510 29.8 <19 – – 3
Jonsson (69) 2019 Sweden European ethnic group – 205 70 34.1 – 40.9 – 3
Khandaker (70) 2019 Bangladesh Multi-ethnic group 2015.01–2016.12 726 170 23.4 <18 38.2 – 1
Påhlman (71) 2019 Sweden European ethnic group 2017.1–2017.3 264 109 41.2 10–17 46.5 – 1
Andrews (72) 2019 Uganda Black ethnic group NA-2015 93 33 35.4 2–17 43.2 – 2
Rafique (73) 2020 Pakistan European ethnic group 2010–2016 658 96 14.5 – 41.7 – 3
Jahan (74) 2020 Indonesia Mongolian ethnic group 2017.3–2017.8 123 15 12.1 0–18 43.8 – 4
Hollung (75) 2020 Norway European ethnic group 2008–2017 2,302 898 39 – 42.1 – 1
Yamagishi (76) 2021 Japan Mongolian ethnic group 2017.4–2018.3 135 46 34 4–8 – – 3
Duke (77) 2021 Nigeria Black ethnic group 2017.12–2018.07 388 130 33.5 4–15 40.9 ILAE in 2014 1
Al-Garni (78) 2021 Saudi arabia European ethnic group 2014–2019 679 196 28.8 0.7–17.8 43.1 – 1
Bambi (79) 2021 Uganda Black ethnic group 2017.11–2018.05 224 138 61.6 2–12 37.5 – 3
Karim (80) 2022 Bangladesh Multi-ethnic group 2015.01–2016.12 726 170 23.4 <18 – ILAE in 2017 1
Szpindel (81) 2022 Canada European ethnic group 1999.01.01–2012.12.31 302 127 42 10–13 44.3 – 1
Linton (82) 2022 Sweden European ethnic group NA-2018 3,902 1,291 33 3–18 42.3 – 1

Summary of articles.

3.3. Prevalence of epilepsy

As shown in Figure 2, the total prevalence of epilepsy in CP was 38.0% (95% CI: 34.8%–41.2%), and significant heterogeneity was found in the study I2  =  94.8%, P <  0.001). Table 2 shows a statistically significant difference between clinical sample-based and population-based studies (P <  0.001). As shown in Figure 2 and Table 2, 32 articles were clinical sample-based studies. The prevalence of epilepsy was 46.4% (95% CI: 41.4%–51.5%), with significant heterogeneity (I2 = 88.3%, P < 0.001). As shown in Figure 2, 40 articles were population-based studies. The prevalence of epilepsy was 31.6% (95% CI: 28.7%–34.5%), with significant heterogeneity (I2 = 91.9%, P < 0.001).

Figure 2

Figure 2

Forest plot of meta-analysis of prevalence of epilepsy in CP.

Table 2

Subgroup Number of studies N Event I 2 P value (95% CI) Prevalence (%) Results of meta-regression for prevalence of CP
Low High P-value Exp (b) 95% CI
Clinical sample-based study 32 7,224 3,016 88.3 <0.001 0.414 0.515 46.4 <0.001 0.8144525 0.8043876 to 0.912799
Population-based study 40 46,745 14,643 91.9 <0.001 0.287 0.345 31.6

According to the sample source in the articles, the estimated prevalence of epilepsy in CP.

3.4. Subgroup analysis of clinical sample-based studies

As shown in Table 3, the prevalence of epilepsy in males with CP was 47.4%, and the prevalence of epilepsy in females with CP was 49.2%. The prevalence of epilepsy in 1981, 1989, and 1993 ILAE was 44.3%, and the majority of epilepsy in 2014 and 2017 ILAE was 44.9%. According to the ethnic group, the prevalence of epilepsy in the European ethnic group was 46.6%, the prevalence of epilepsy in the Mongolian ethnic group was 32.8%, the prevalence of epilepsy in the Black ethnic group was 48.6%, and the prevalence of epilepsy in the multi-ethnic group was 64.4%. According to the national income level, the prevalence of epilepsy in low-and middle-income countries was 47.0%, and the prevalence of epilepsy in high-income countries was 43.0%. The prevalence of epilepsy in CP was 39.9% from 1998 to 2003, 50.2% from 2011 to 2016, and 46.7% from 2017 to 2022.

Table 3

Subgroup Number of studies N Event I 2 P value (95% CI) Prevalence (%) P value between groups
Gender
Female 12 784 374 26.0 0.188 0.433 0.551 49.2 0.760
Male 12 1,109 504 56.8 0.008 0.407 0.542 47.4
Diagnostic criteria for epilepsy developed by the ILAE
1981, 1989 and 1993 13 2,581 1,090 67.2 <0.001 0.390 0.496 44.3 0.940
2014 and 2017 4 837 340 91.5 <0.001 0.275 0.622 44.9
Ethnic group
Europoid 19 3,832 1,673 85.8 <0.001 0.404 0.529 46.6 0.329
Mongoloid 4 1,444 385 95.0 <0.001 0.108 0.548 32.8
Black 7 1,738 823 86.3 <0.001 0.387 0.586 48.6
Multi-ethnic mixed 2 210 135 0 =0.598 0.564 0.725 64.4
National income level
Low-and Middle-income 27 6,062 2,543 90.9 <0.001 0.408 0.533 47.0 0.588
High-income 5 1,162 473 72.7 0.005 0.342 0.517 43.0
Publication time
1998–2003 7 1,469 570 61.7 0.016 0.359 0.438 39.9 0.587
2011–2016 7 1,598 767 80.0 <0.001 0.408 0.597 50.2
2017–2022 18 4,157 1,679 92.9 <0.001 0.382 0.552 46.7

The estimated prevalence of epilepsy in CP based on clinical sample studies.

3.5. Subgroup analysis of population-based studies

As shown in Table 4, the prevalence of epilepsy in males with CP was 36.2%, and the prevalence of epilepsy in females with CP was 31.4%. The prevalence of epilepsy in 1981, 1989, and 1993 ILAE was 33.2%, and the majority of epilepsy in 2014 and 2017 ILAE was 32.4%. According to the ethnic group, the prevalence of epilepsy in the European ethnic group was 31.6%, the prevalence of epilepsy in the Mongolian ethnic group was 29.6%, the prevalence of epilepsy in the Black ethnic group was 38.1%, and the prevalence of epilepsy in the multi-ethnic group was 29.6%. According to the national income level, the prevalence of epilepsy in low- and middle-income countries was 30.7%, and that in high-income countries was 32.1%. The prevalence of epilepsy in CP was 26.4% from 1998 to 2003, 34.0% from 2004 to 2010, 32.7% from 2011 to 2016, and 31.5% from 2017 to 2022. The distribution of epilepsy prevalence is shown in Figure 3.

Table 4

Subgroup Number of studies N Event I 2 P value (95% CI) Prevalence (%) P value between groups
Gender
Female 5 4,342 1,463 74.6 0.003 0.212 0.417 31.4 0.586
Male 5 5,998 1,972 83.4 <0.001 25.7 46.6 36.2
Diagnostic criteria for epilepsy developed by the ILAE
1981, 1989 and 1993 12 20,715 6,864 87.4 <0.001 29.3 37.0 33.2 0.447
2014 and 2017 2 1,114 300 72.8 0.55 28.8 36.0 32.4
Ethnic group
Europoid 24 27,275 8,867 87.6 <0.001 0.284 0.348 31.6 0.909
Mongoloid 4 9,450 2,814 40.2 0.171 0.253 0.338 29.6
Black 4 1,065 378 93.5 <0.001 0.192 0.570 38.1
Multi-ethnic mixed 8 8,955 2,584 65.5 0.005 0.263 0.329 29.6
National income level
Low- and middle-income 15 15,643 4,545 92.0 <0.001 0.251 0.363 30.7 0.619
High-income 25 31,102 10,098 77.2 <0.001 0.298 0.344 32.1
Publication time
1998–2003 4 1,854 392 82.0 <0.001 0.161 0.367 26.4 0.597
2004–2010 4 707 227 58.1 0.067 0.245 0.435 34.0
2011–2016 11 19,811 6,573 87.6 <0.001 0.288 0.367 32.7
2017–2022 21 24,373 7,451 86.9 <0.001 0.281 0.348 31.5

The estimated prevalence of epilepsy in CP based on population studies.

Figure 3

Figure 3

Prevalence of epilepsy in CP in different countries or regions in population-based study.

3.6. Based on the characteristics of CP to explore the subgroup factors related to comorbid epilepsy in CP

As shown in Table 5, in terms of gestational age, the prevalence of epilepsy in preterm CP (36.4%, 95% CI: 28.4%–44.4%) was lower than in term birth (45.7%, 95% CI: 38.9%–45.7%). Regarding birth weight, the prevalence of epilepsy in low birth weight CP (44.9%, 95% CI: 30.4%–59.4%) was lower than that in normal weight children (53.4%, 95% CI: 38.7%–68.0%). Regarding birth asphyxia, the prevalence of epilepsy in CP with birth asphyxia (46.6%, 95% CI: 33.4%–59.8%) was higher than that without birth asphyxia (41.7%, 95% CI: 38.1%–52.0%). Regarding NE, the prevalence of epilepsy in CP with NE (66.9%, 95% CI: 56.6%–77.2%) was significantly higher than that without NE (42.1%, 95% CI: 35.3%–48.8%) (P < 0.001). Regarding a family history of epilepsy, the prevalence of epilepsy in CP with a family history of epilepsy (89.2%, 95% CI: 81.1%–97.3%) was significantly higher than that without a family history of epilepsy (49.0%, 95% CI: 44.4%–53.7%) (P < 0.001). Regarding EEG abnormalities, the prevalence of epilepsy in CP with EEG abnormalities (60.8%, 95% CI: 45.3%–76.3%) was significantly higher than that without EEG abnormalities (24.0%, 95% CI: 6%–42.0%) (P = 0.009). Regarding cranial imaging abnormalities, the prevalence of epilepsy in CP with cranial imaging abnormalities (60.8%, 95% CI: 57.8%–37.2%) was significantly higher than that without cranial imaging abnormalities (36.3%, 95% CI: 24.3%–48.3%) (P = 0.009).

Table 5

Subgroup Number of studies N Event I 2 P value (95% CI) Prevalence (%) Results of meta-regression for prevalence of CP
P-value Exp (b) 95% CI
Gestational age
<37 w 13 4,862 1,405 78.7 <0.001 0.284 0.444 36.4 0.086 1.095615 0.9863146 to 1.217028
≥37 w 13 5,755 2,306 73.7 <0.001 0.389 0.457 45.7
Birth weight
<2,500 g 5 4,267 1,242 88.2 <0.001 0.304 0.594 44.9 0.331 1.092679 0.8939114 to 1.335644
≥2,500 g 4 4,928 1,969 90.7 <0.001 0.387 0.680 53.4
Neonatal seizures
Yes 12 742 437 78.8 <0.001 0.566 0.772 66.9 <0.001 0.7750931 0.6820871 to 0.8807809
No 12 5,485 1,885 80.6 <0.001 0.353 0.488 42.1
Birth asphyxia
Yes 3 307 146 58.5 0.09 0.334 0.598 46.6 0.446 1.063259 0.8689285 to 1.301051
No 3 284 118 0.0 0.866 0.381 0.520 41.7
Family history of epilepsy
Yes 6 63 52 0.0 <0.001 0.811 0.973 89.2 <0.001 0.6752944 0.5988776 to 0.7614619
No 6 910 439 0.0 <0.001 0.444 0.537 49.0
EEG abnormalities
Yes 3 487 274 84.4 0.002 0.453 0.763 60.8 0.009 0.684606 0.4567173 to 1.026204
No 3 90 21 0.0 0.731 0.06 0.420 24.0
Cranial imaging abnormalities
Yes 8 801 450 63.4 0.008 0.502 0.655 57.8 0.009 0.8061711 0.6925094 to 0.9384882
No 8 342 110 43.5 0.088 0.243 0.483 36.3
CNS pathological changes based on MRICS
Predominantly White matter injuries 3 104 56 4.7 0.350 0.428 0.69 55.9 0.127 0.9707238 0.9336145 to 1.009308
Predominantly White matter injuries 3 219 94 53.9 0.114 0.153 0.577 36.5
Malformations 5 730 385 0.0 0.939 0.479 0.578 52.8
Miscellaneous 3 94 39 25.0 0.264 0.256 0.620 43.8
Normal 6 247 95 2.1 0.403 0.308 0.504 40.6
Cognitive/intellectual status
Normal 8 927 159 5.2 0.390 0.121 0.238 17.9 <0.001 1.206163 1.161264 to 1.252798
Mild 4 139 53 0.0 0.914 0.215 0.515 38.5
Moderate 3 105 70 0.0 0.577 0.568 0.786 67.7
Severe 4 237 175 5.5 0.365 0.688 0.815 75.2
Clinical type of CP
Spastic type 16 10,482 3,277 80.1 <0.001 0.374 0.480 42.7 0.528 1.013248 0.9720165 to 1.056228
Dyskinetic type 19 1,185 582 55.0 0.002 0.447 0.611 52.9
Ataxia type 15 760 237 41.5 0.047 0.290 0.491 39.1
Mixed type 9 284 129 60.0 0.010 0.364 0.643 45.9
Topographical type of CP
Quadriplegia 21 2,367 1,350 62.1 <0.001 0.570 0.665 61.8 <0.001 0.8863164 0.8414422 to 0.9335837
Diplegia 21 2,049 476 13.7 0.280 0.216 0.309 26.3
Hemiplegia 21 1,879 570 72.0 <0.001 0.318 0.487 40.2

Subgroup analysis of CP comorbid epilepsy based on the characteristics of CP.

Regarding CNS abnormalities based on MRICS, the prevalence from high to low was predominantly gray matter injuries (55.9%, 95% CI: 42.8%–69.0%), brain malformation (52.8%, 95% CI: 47.9%–57.8%), miscellaneous (43.8%, 95% CI: 47.9%–57.8%), normal (40.6%, 30.8%–50.4%) and predominantly white matter injuries (36.5%, 95% CI: 15.3%–57.7%). Regarding cognition/intelligence, the prevalence significantly increased with the degree of cognition/intelligence, followed by normal (17.9%, 95% CI: 12.1%–23.8%), mild (38.5%, 95% CI: 21.5%–51.5%), moderate (67.7%, 95% CI: 56.8%–78.6%), severe (75.2%, 95% CI: 68.8%–81.5%) (P < 0.001). Regarding the clinical type of CP, the prevalence from high to low was the dyskinetic type (52.9%, 95% CI: 44.7%–61.1%), mixed type (45.9%, 95% CI: 36.4%–64.3%), spastic type (42.7%, 95% CI: 37.4%–48.0%) and ataxia type (39.1%, 95% CI: 29.0%–49.1%). Regarding the topographical type of CP, the prevalence from high to low was quadriplegia (61.8%, 95% CI: 57.0%–66.5%), hemiplegia (40.2%, 95% CI: 31.8%–48.7%), and diplegia (26.3%, 95% CI: 21.6%–30.9%) (P < 0.001).

3.7. Publication bias

The funnel plot was used to assess the presence of publication bias, revealing an evident asymmetry in the overall prevalence of epilepsy. However, we conducted separate analyses by sample source, resulting in symmetrical funnel plots for both clinical case-based and population-based studies (see Figure 4). The application of Egger's test indicated a significant publication bias in the meta-analysis (t = 2.39, P < 0.05). Further analysis utilizing Egger's test based on sample source revealed no significant publication bias in the clinical sample-based study (t = 0.34, P = 0.733) and population-based study (t = −0.50, P = 0.623), as depicted in Figure 5.

Figure 4

Figure 4

The funnel plot of the total prevalence of epilepsy in CP. (A) All studies (B) Clinical sample-based study (C) Population-based study.

Figure 5

Figure 5

Egger's test of the prevalence of epilepsy in CP. (A) All studies (B) Clinical sample-based studies (C) Population-based studies.

3.8. Sensitivity analysis and meta-regression analysis

A sensitivity analysis was conducted using the single-article removal method, and no studies were found to affect the overall results significantly. Meta-regression analysis was then performed on the included articles, with the prevalence of epilepsy in CP as the dependent variable. Independent variables for the meta-regression analysis included the sample source of the articles, gestational age, birth weight, birth asphyxia, NE, family history of epilepsy, CNS abnormalities based on MRICS, EEG abnormalities, cranial imaging abnormalities, cognitive/intellectual status, clinical type of CP, and topographical type of CP. The results revealed significant heterogeneity among the sample source of articles, NE, family history of epilepsy, EEG abnormalities, imaging abnormalities, intellectual/cognitive impairment, and topographical type of CP (P < 0.05), as illustrated in Tables 2, 5.

4. Discussion

The total prevalence of epilepsy in CP in this study was 38.0%, and epilepsy in children with CP was 46.4% in a clinical case-based study and 31.6% in a population-based study. The number of individuals with CP in included articles was enough to represent the prevalence of epilepsy in CP, which can reflect the prevalence of epilepsy in CP to some extent. In clinical sample-based studies, the prevalence of epilepsy in CP was generally high, which might be caused by the individuals were mainly from medical institutions, or the individuals admitted were generally more severe. They are more likely to have comorbidities such as intellectual disability, epilepsy, and speech disorders, leading to overestimating the prevalence of epilepsy in CP (83). In contrast, CP with milder symptoms might not go to hospitals or rehabilitation facilities for rehabilitation, thus missing some individuals with mild to moderate CP that were less likely to develop epilepsy. In population-based studies, the prevalence of CP at the national level was unknown because some countries or regions need a specific population-based national registry (48). Therefore the studies only covered part of the region and represented the prevalence of epilepsy in that region or country. However, even so, population-based studies can cover a wider area than clinical sample-based studies and provide a more precise and scientific prevalence of epilepsy in children with CP.

In terms of ethnic group, the prevalence of epilepsy in CP was significantly higher in Black-majority countries (48.6% and 38.1%) than in other-majority countries in both clinical sample-based and population-based studies, which may be associated with poor economics. In the clinical sample-based study, the prevalence of epilepsy was higher in low- and middle-income countries than in high-income countries (47.0% vs. 43.0%). Firstly, due to the low level of parental education, lack of CP-related professional knowledge, poor perinatal and postpartum management, and poor early diagnosis and intervention, CP is generally more severe in motor and cognitive impairment, and the possibility of secondary complications such as epilepsy increases (84–86). Secondly, compared to high-income countries, children from low- and middle-income countries were more often admitted to hospitals for treatment of severe CP, and this segment of the CP population had a high prevalence of epilepsy (87). In contrast, in population-based studies, the prevalence of epilepsy in low- and middle-income countries and high-income countries was very close (30.7% vs. 32.1%), which might be responsible for filling that missing segment of children with mild to moderate CP. The number of articles we included (n = 43) and individuals (n = 31,098) were highest in countries of predominantly European origin, which may give a more accurate prevalence of epilepsy in this segment of the CP population (46.6% and 31.2%). The low prevalence of epilepsy in Mongolian-majority countries (32.8% and 29.6%) might be because we restricted the search language to English and missed some articles published in non-English languages. Moreover, the number of articles included in this study was generally low (n = 8), and there might be some publication bias. The veracity of the results remains to be verified by a large number of original studies.

Based on the time of publication of the article, it was found that the prevalence of epilepsy in CP was low in 1998–2002 (39.9% and 26.4%) compared with other periods, and the prevalence stabilized in 2011–2022, both in clinical sample-based studies and population-based studies. Our interpretation of the results was that it might not be that the prevalence of epilepsy in CP has increased in the last decade. The diagnostic sensitivity or specificity of epilepsy had increased with the updating of epilepsy diagnostic criteria and the promotion of improved assessment techniques, resulting in more children with CP being accurately diagnosed with epilepsy. For example, epilepsy diagnosis in the articles from 1998 to 2002 relied more on the clinical history and symptoms for diagnosis, whereas articles from 2011 to 2022 used clinical symptoms combined with EEG more often. Secondly, it also correlated with the number of articles included. Our inclusion was mainly after 2010 (n = 57) and generally less before 2010 (n = 15), which might have some publication bias. Regarding gender, the prevalence of CP in males was significantly higher than in females. However, there was no significant difference between groups in the prevalence of epilepsy in the clinic-based and population-based studies, suggesting that gender had a negligible effect on the prevalence of epilepsy.

Several articles suggested that a history of NS was associated with a high risk of epilepsy in CP and was a strong predictor of epilepsy in children with CP. Levene et al. (88) reported that NS adversely affected the developmental progression of CNS and can lead to intrinsic brain lesions that might predispose to cognitive, behavioral, or epileptic problems later in life. It was postulated that NS, especially those starting within the first 72 h, was a significant risk factor for developing epilepsy (31). In addition, Mert et al. (20) showed that children with CP with a history of NS were 3.3 times more likely to have a poor prognosis for epilepsy than those without a history of neonatal seizures. Therefore, a history of NS in CP was a significant related factor for the development and poor prognosis of epilepsy.

Our study found a high prevalence of epilepsy in CP with a family history of epilepsy (89.2%) compared to those without a family history of epilepsy (49.0%). Mert et al. (20) showed that the prevalence of epilepsy in children with CP with a family history of epilepsy was 5.5 times higher than that in children without a family history of epilepsy. Therefore, it can be hypothesized that genetic factors play an essential role in the pathogenesis of epilepsy development and can be a significant predictor of seizures in children with CP.

It is well known that intellectual disability and CP often occur together (89). The prevalence of epilepsy in CP with cognitive/intellectual disability increased with the degree of intellectual disability, probably because CP with epilepsy have more severe brain injury. Thus the coexistence of intellectual disability and epilepsy was high, and each seizure might aggravate the brain injury in children with CP and have some effect on their intelligence (12, 47). According to the study conducted by Karatoprak et al. (31), the prevalence of epilepsy in children with severe intellectual disabilities was found to be 8.9 times higher compared to children with average intelligence. El-tallowy et al. (47) showed that children with CP might suffer from extensive brain injury to various parts of the brain, such as brain gray matter, deep brain white matter, and the central nucleus. Therefore, they were vulnerable to intellectual disability and epilepsy. Cognitive/intellectual disability was uncommon in diplegia because it generally did not damage brain gray matter. In contrast, epilepsy and cognitive/intellectual disability were more common and severe in quadriplegia because of extensive brain injury (36). Although cognitive/intellectual disability is more common in children with CP with severe brain injury, and the possibility of seizures is higher, some children with severe brain injury have normal intelligence and do not often accompany by epilepsy. This may be related to the site of injury. For example, more than half of the intelligence of dyskinetic CP with deep gray matter injury is normal and may not be accompanied by epilepsy (90).

Further study of the possible risk of epilepsy development and its relationship with EEG and cranial imaging might help to find the risk factors associated with epilepsy affecting CP (16). In this study, the cranial imaging applied in the included articles included CT and MRI. Cranial MRI was the most recommended neuroimaging modality. Widely-adopted MRICS could be used for brain abnormalities—malformations, predominantly white matter injuries, mostly gray matter injuries, and miscellaneous and normal imaging. It helps to provide further insights into the nature of the abnormalities to aid the diagnosis, treatment planning, and monitoring of patients with CP. The epilepsy diagnosis was based on family and personal history and symptoms, and EEG was a gold standard for diagnosis (91). Hanci et al. (32) showed that widespread or focal epileptiform abnormalities might be essential in developing CP epilepsy. The data showed that the likelihood of co-morbid epilepsy would be higher in CP with the presence of EEG abnormalities (60.8%) and cranial imaging abnormalities (57.8%) and was statistically different between groups of children with CP without epilepsy (P < 0.05). That suggests the importance of early and effective EEG and cranial imaging combined with clinical history for detecting epilepsy in CP.

Many studies have shown that gray matter injury was a significant cause of seizures compared to white matter injury. For example, temporal and frontal lobe injury was highly epileptogenic (7, 46, 73). This study also validated the higher odds of seizures in CP with predominantly gray matter injury (55.9%) compared to predominantly white matter injuries (36.5%) in the present study. However, if the brain white matter was affected or the damage was limited to the basal ganglia and thalamus, the likelihood of epilepsy became low (33). In addition, this study showed a 52.8% prevalence of epilepsy in brain malformations. Carlsson et al. (46) found an increased frequency of seizures in young people with CP with CNS infections and malformations with the injury to the brain gyrus.

Due to the heterogeneity of symptoms and complications of CP, there was no clear global consensus on the type of CP (1, 92). Therefore, in this study, we analyzed CP according to its clinical type (spastic, dyskinetic, ataxic, and mixed) and topographical type (hemiplegia, diplegia, and quadriplegia) based on the typing characteristics of the included articles to explore the differences. This study showed that clinical type was not responsible for the prevalence of epilepsy in CP, but the topographical type mainly affected seizures in children with CP (P < 0.001). This study showed that quadriplegia was the leading cause of seizures affecting children with CP (61.8%), followed by hemiplegia (40.2%) and diplegia (26.3%). Because quadriplegia was characterized by extensive brain injury or brain softening secondary to ischemic-hypoxic events with a higher degree of injury and a high prevalence of epilepsy compared to hemiplegia and diplegia (33). Most hemiplegia will have focal cortical injury or infarction due to perinatal arterial ischemic infarction and a higher prevalence of epilepsy. In contrast, diplegic injury tended to be predominantly periventricular leukomalacia, not involving cortical gray matter, and had a lower prevalence of epilepsy (13, 93, 94).

In terms of clinical type, our study included 12,711 young people with CP, 82.5% of them were spastic CP, the most clinical type of CP. And 42.7% of them had epilepsy, the epilepsy prevalence rate was lower than that of the dyskinetic and mixed types. The reason for this was that in addition to the spastic CP only described in some articles, we also included the description of spastic diplegia, spastic hemiplegia, and spastic quadriplegia in a unified category as spastic CP, with a higher proportion of young people with spastic diplegia (34%), resulting in a lower overall prevalence of epilepsy in spastic CP than that in the other clinical types. In this study, children with dyskinetic type had the highest prevalence in studies with clinical as a typing criterion. However, children with simple dyskinetic CP with only basal ganglia lesions were less likely to have epilepsy. There are some reasons for that. First, the dyskinetic type had a higher incidence of neonatal seizures (53). Second, brain injuries in the temporal and frontal lobes were high risk of suffering seizure (53). Third, the more dif ficulty distinguishing between complex partial seizures and the dyskinetic pattern caused an overdiagnosis of epilepsy (53). Fourth, the number of dyskinetic-type individuals in each article was generally few, which had a certain bias from the results. In addition, the ataxic type had the lowest prevalence of epilepsy, but even then, there was a significant incidence of epilepsy (39.1%). We interpreted the reason for this to be that although the prevalence of epilepsy due to cerebellar injury was less likely, various high-risk factor injury were not limited to the cerebellum because the diagnosis of CP was based on clinical symptoms (14). The type of diagnosis of CP might be limited only to the most significant clinical symptoms. Therefore, our interpretation of the results preferred that the severity of the injury and the area of brain injury in CP may be the main factors affecting the onset of epilepsy rather than clinical typing.

The high prevalence of epilepsy in CP might be due to common etiology and risk factors. It was unclear why the same lesions cause CP with or without epilepsy, and we speculated that it might be due to genetic susceptibility. In this study, the prevalence of epilepsy in children with CP born prematurely with low birthweight was lower than that in children born at term and average weight, suggesting that preterm birth and low birth weight were not significant risk factors contributing to seizures in children with CP. Prematurity is caused predominantly periventricular leukomalacia the leading cause of diplegia in preterm infants. In contrast, due to brain gray matter injury, CP was more common in full-term infants (12, 16, 95, 96). Since epilepsy was uncommon in children with spastic diplegia and white matter injury, epilepsy was rarely seen in preterm infants (95).

5. Advantages of this study

The advantages of this study include several key points. Firstly, it represents the first and most comprehensive systematic review and meta-analysis conducted on the prevalence of epilepsy in individuals with CP. This study encompasses a larger number of included articles and individuals, resulting in more robust prevalence estimates and increased confidence in the findings. Secondly, a meticulous approach was taken to categorize the articles into clinical sample-based and population-based studies based on the source of samples. This division allows for a more refined analysis and comparison of prevalence rates. Additionally, subgroup analyses were conducted considering factors such as gender, ethnic group, and national income level. This approach helps to mitigate the heterogeneity among studies and provides a more scientifically sound method to assess the prevalence of epilepsy in different subgroups. Thirdly, the study delves into a comprehensive analysis of various confounding factors associated with CP, such as gestational age, birth weight, history of NE, cognitive/intellectual status, and the specific type of CP. By considering these factors, the prevalence of epilepsy was examined from a more comprehensive perspective. Moreover, potential sources of heterogeneity and factors influencing the prevalence of epilepsy were identified. This aids in better understanding the variations observed in the prevalence estimation and provides insights into the associated factors contributing to the occurrence of epilepsy in individuals with CP. Overall, the advantages of this study lie in its comprehensive nature, meticulous categorization and analysis of factors, and the identification of potential sources of heterogeneity. These aspects contribute to a more thorough understanding of the prevalence of epilepsy in individuals with CP.

6. Limitations

There are several limitations to consider in this study. Firstly, we did not conduct an age-based meta-analysis of epilepsy prevalence due to the wide age ranges covered in the included studies, which made age group comparisons unfeasible. However, it is worth noting that previous research has shown a higher occurrence of epilepsy in the early years of individuals with CP, with most seizures occurring within the first year of life (14, 17, 22, 30, 33). Furthermore, some population-based studies on adolescents have an age range of up to 19 years, exceeding the commonly accepted age of 18 (45, 58, 62, 68). This necessitated our decision to divide the age range accordingly. Moreover, the single combined estimate of prevalence should be interpreted with caution due to several limitations. Firstly, heterogeneity exists even in subgroup analyses, which is often difficult to avoid in epidemiological studies (97). Secondly, variations in prevalence between studies may stem from factors such as sample source, different definitions of CP and epilepsy, representativeness of samples, and the specificity of diagnostic tools. Many studies relied on clinical history and symptoms to confirm epilepsy, which can result in both under- and over-diagnosis. Thirdly, the data of some articles are not comprehensive enough, such as the failure to reflect the time range of data collection, diagnostic criteria of epilepsy, age range and female ratio on the Table 1. Some articles were excluded from subgroup analysis due to the lack of CP characteristics data, and the number of articles included in subgroup analysis may have a certain bias on the results. Additionally, the high prevalence of epilepsy in CP observed in clinical sample-based studies may be due to an over-representation of more severe individuals admitted to medical institutions for intellectual disability, epilepsy, motor disorders, and speech disorders. Furthermore, it is essential to note that this study excluded unpublished articles and articles published in non-English languages, which could have resulted in an underestimation or overestimation of the true prevalence of epilepsy in CP. Lastly, differences in the characteristics of the individuals in the study may have influenced the results. While this study provides valuable insights, these limitations should be considered when interpreting the findings.

7. Conclusion

In summary, our findings indicate that more than one-third of young people with CP experience epilepsy, with an overall prevalence of 38.0%. Prevalence rates differ based on the study type, with clinic-based studies showing a prevalence of 46.4% and population-based studies showing a prevalence of 31.6%. The source of CP cases in the articles emerged as a significant factor contributing to the heterogeneity in epilepsy prevalence. Our analysis suggests NE, a family history of epilepsy, abnormal EEG findings, abnormal cranial imaging, severe intellectual disability, and quadriplegia may be associated with comorbid epilepsy in CP. Given the high prevalence of epilepsy in CP, it is recommended that children with these related factors be followed up regularly for a long time. Cranial imaging and EEG should be performed on young people with CP suspected of having a risk of seizures, and appropriately use anticonvulsant medication to reduce seizure frequency in individuals with CP. Furthermore, systematic investigations into the prevalence of epilepsy in individuals with CP and exploring factors contributing to seizures may also shed light on potential shared genetic mechanisms, providing new insights into the genetic patterns and possible overlaps between these disorders.

Statements

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Author contributions

CG and JG are responsible for the conception and design of the article, the revision of the paper, and the overall responsibility of the study; CG, PZ, and XW are responsible for the implementation of the study and feasibility analysis, statistical processing; CG, BL and JG were responsible for literature retrieval, data collection, and collation; XW, PZ and WP were responsible for quality assessment. CG, SZ, ZJ, and WP were responsible for the analysis and interpretation of the results. CG, JG, AL and BW wrote and revised the paper. All authors contributed to the article and approved the submitted version.

Funding

The Heilongjiang Provincial Natural Science Foundation Project (No. LH2020H006) and fund Basic scientific research operating expenses of provincial institutions of higher learning in Heilongjiang Province (NO.2019-KYYWF-1366 and No.2022-KYYWF-0653) supported this study.

Acknowledgments

We thank all the authors, editors, and reviewers who contributed to this study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2023.1189648/full#supplementary-material

References

  • 1.

    Rosenbaum P Paneth N Leviton A Goldstein M Bax M Damiano D et al A report: the definition and classification of CP April 2006. Dev Med Child Neurol Suppl. (2007) 109:8–14.

  • 2.

    Centers for disease control and prevention. Data and statistics for CP (2021). Available at:https://www.cdc.gov/ncbddd/cp/data.html(Accessed May, 2021).

  • 3.

    Fisher RS Acevedo C Arzimanoglou A Bogacz A Cross JH Elger CE et al ILAE Official report: a practical clinical definition of epilepsy. Epilepsia. (2014) 55(4):475–82. 10.1111/epi.12550

  • 4.

    Depositario-Cabacar DF Zelleke TG . Treatment of epilepsy in children with developmental disabilities. Dev Disabil Res Rev. (2010) 16(3):239–47. 10.1002/ddrr.116

  • 5.

    The definition and classification of cerebral palsy. Dev Med Child Neurol. (2007) 49(s109):1–44. 10.1111/j.1469-8749.2007.00001.x

  • 6.

    Cooper MS Mackay MT Dagia C Fahey MC Howell KB Reddihough D et al Epilepsy syndromes in cerebral palsy: varied, evolving and mostly self-limited. Brain. (2023) 146(2):587–99. 10.1093/brain/awac274

  • 7.

    Cooper MS Mackay MT Fahey M Reddihough D Reid SM Williams K et al Seizures in children with cerebral palsy and white matter injury. Pediatrics. (2017) 139(3):e20162975. 10.1542/peds.2016-2975

  • 8.

    Prasad R Verma N Srivastava A Das BK Mishra OP . Magnetic resonance imaging, risk factors and co-morbidities in children with cerebral palsy. J Neurol. (2011) 258(3):471–8. 10.1007/s00415-010-5782-2

  • 9.

    Aicardi J . Epilepsy in brain-injured children. Dev Med Child Neurol. (1990) 32(3):191–202. 10.1111/j.1469-8749.1990.tb16925.x

  • 10.

    WHO. Global accelerated action for the health of adolescents (AA-HA!): guidance to support country implementation. Geneva. (2017).

  • 11.

    Hoy D Brooks P Woolf A Blyth F March L Bain C et al Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. (2012) 65(9):934–9. 10.1016/j.jclinepi.2011.11.014

  • 12.

    Kwong KL Wong SN So KT . Epilepsy in children with cerebral palsy. Pediatr Neurol. (1998) 19(1):31–6. 10.1016/s0887-8994(98)00011-3

  • 13.

    Zafeiriou DI Kontopoulos EE Tsikoulas I . Characteristics and prognosis of epilepsy in children with cerebral palsy. J Child Neurol. (1999) 14(5):289–94. 10.1177/088307389901400504

  • 14.

    Bruck I Antoniuk SA Spessatto A Bem RS Hausberger R Pacheco CG . Epilepsy in children with cerebral palsy. Arq Neuropsiquiatr. (2001) 59(1):35–9. 10.1590/s0004-282(2001000100008

  • 15.

    Sianturi P Syarifuddin A Saing B . Incidence of epilepsy among patients with cerebral palsy (CP) in yayasan pemeliharaan anak cacat (YPAC) â medan. Med J Indones. (2002) 11(3):158–63. 10.13181/mji.v11i3.69

  • 16.

    Senbil N Sonel B Aydin OF Gürer YK . Epileptic and non-epileptic cerebral palsy: EEG and cranial imaging findings. Brain Dev. (2002) 24(3):166–9. 10.1016/s0387-7604(02)00025-6

  • 17.

    Singhi P Jagirdar S Khandelwal N Malhi P . Epilepsy in children with cerebral palsy. J Child Neurol. (2003) 18(3):174–9. 10.1177/08830738030180030601

  • 18.

    Kułak W Sobaniec W . Risk factors and prognosis of epilepsy in children with cerebral palsy in north-eastern Poland. Brain Dev. (2003) 25(7):499–506. 10.1016/s0387-7604(03)00040-8

  • 19.

    Zelnik N Konopnicki M Bennett-Back O Castel-Deutsch T Tirosh E . Risk factors for epilepsy in children with cerebral palsy. Eur J Paediatr Neurol. (2010) 14(1):67–72. 10.1016/j.ejpn.2009.06.002

  • 20.

    Mert GG Incecik F Altunbasak S Herguner O Mert MK Kiris N et al Factors affecting epilepsy development and epilepsy prognosis in cerebral palsy. Pediatr Neurol. (2011) 45(2):89–94. 10.1016/j.pediatrneurol.2011.03.001

  • 21.

    Frank-Briggs AI Alikor EAD . Sociocultural issues and causes of cerebral palsy in port harcourt, Nigeria. Niger J Paediatr. (2011) 38(3):115–9. 10.1111/j.1469-8749.2012.04283.x

  • 22.

    Aronu AE Ibekwe RC Ojinnaka NC . Epilepsy in Nigerian children with cerebral palsy in enugu. J Pediatr Neurol. (2013) 11(01):023–7. 10.3233/JPN-120592

  • 23.

    Kakooza-Mwesige A Forssberg H Eliasson AC Tumwine JK . Cerebral palsy in children in Kampala, Uganda: clinical subtypes, motor function and co-morbidities. BMC Res Notes. (2015) 8:166. 10.1186/s13104-015-1125-9

  • 24.

    Keeratisiroj O Thawinchai N Siritaratiwat W Buntragulpoontawee M . Prognostic predictors for ambulation in Thai children with cerebral palsy aged 2 to 18 years. J Child Neurol. (2015) 30(13):1812–8. 10.1177/0883073815582267

  • 25.

    Bearden DR Monokwane B Khurana E Baier J Baranov E Westmoreland K et al Pediatric cerebral palsy in Botswana: etiology, outcomes, and comorbidities. Pediatr Neurol. (2016) 59:23–9. 10.1016/j.pediatrneurol.2016.03.002

  • 26.

    Minocha P Sitaraman S Sachdeva P . Clinical spectrum, comorbidities, and risk factor profile of cerebral palsy children: a prospective study. J Pediatr Neurosci. (2017) 12(1):15–8. 10.4103/1817-1745.205622

  • 27.

    Gincota Bufteac E Andersen GL Torstein V Jahnsen R . Cerebral palsy in moldova: subtypes, severity and associated impairments. BMC Pediatr. (2018) 18(1):332. 10.1186/s12887-018-1305-6

  • 28.

    Gürkan F Gökben S Serin HM Yılmaz S Aktan G Tekgül H et al Determining risk factors of epilepsy in children with cerebral palsy: a retrospective study. J Pediatr Res. (2018) 5(2):76. 10.4274/jpr.24471

  • 29.

    Sucuoğlu H . Demographic and clinical characteristics of patients with cerebral palsy. İstanbul Med J. (2017) 19(3):219–24. 10.5152/imj.2018.88310

  • 30.

    Aydın K Kartal A Keleş Alp E . High rates of malnutrition and epilepsy: two common comorbidities in children with cerebral palsy. Turk J Med Sci. (2019) 49(1):33–7. 10.3906/sag-1803-79

  • 31.

    Karatoprak E Sözen G Saltık S . Risk factors associated with epilepsy development in children with cerebral palsy. Childs Nerv Syst. (2019) 35(7):1181–7. 10.1007/s00381-019-04152-w

  • 32.

    Hanci F Türay S Dilek M Kabakuş N . Epilepsy and drug-resistant epilepsy in children with cerebral palsy: a retrospective observational study. Epilepsy Behav. (2020) 112:107357. 10.1016/j.yebeh.2020.107357

  • 33.

    Pavone P Gulizia C Le Pira A Greco F Parisi P Di Cara G et al Cerebral palsy and epilepsy in children: clinical perspectives on a common comorbidity. Children (Basel). (2020) 8(1):16. 10.3390/children8010016

  • 34.

    Sadowska M Sarecka-Hujar B Kopyta I . Evaluation of risk factors for epilepsy in pediatric patients with cerebral palsy. Brain Sci. (2020) 10(8):481. 10.3390/brainsci10080481

  • 35.

    Al-Blowi A Al-Mutairi R Ghabbany RM Manaa AM Aloufi MM Ternati GK et al The prevalence of malnutrition and the nutritional status in children with CP and its causes in madinah maternity and children hospital. Curr Pediatr Res. (2020) 24(7):273–80.

  • 36.

    Şık N Sarıoğlu FC Öztekin Ö Sarıoğlu B . Evaluation of the relationship between cranial magnetic resonance imaging findings and clinical status in children with cerebral palsy. Turk J Med Sci. (2021) 51(3):1296–301. 10.3906/sag-2010-187

  • 37.

    Tsige S Moges A Mekasha A Abebe W Forssberg H . Cerebral palsy in children: subtypes, motor function and associated impairments in Addis Ababa, Ethiopia. BMC Pediatr. (2021) 21(1):544. 10.1186/s12887-021-03026-y

  • 38.

    Jibril YN Shamsu KA Muhammad NB Hasheem MG Tukur AR Salisu AD . Determinants of hearing loss in children with cerebral palsy in kano, Nigeria. Niger J Clin Pract. (2021) 24(6):802–7. 10.4103/njcp.njcp_480_20

  • 39.

    Chaudhary S Bhatta NK Poudel P Agrawal J Kalawar RPS Jayswal JP . Profile of children with cerebral palsy at a tertiary hospital in eastern Nepal. BMC Pediatr. (2022) 22(1):415. 10.1186/s12887-022-03477-x

  • 40.

    Mangamba DCK Enyama D Foko LPK Tankou J Njinkui DN Essome H et al Epidemiological, clinical, and treatment-related features of children with cerebral palsy in Cameroon: a hospital-based study. Arch Pediatr. (2022) 29(3):219–24. 10.1016/j.arcped.2022.01.006

  • 41.

    Archana K Saini L Gunasekaran PK Singh P Sahu JK Sankhyan N et al The profile of epilepsy and its characteristics in children with cerebral palsy. Seizure. (2022) 101:190–6. 10.1016/j.seizure.2022.08.009

  • 42.

    Karim T Jahan I Dossetor R Giang NTH Van Anh NT Dung TQ et al Nutritional Status of children with cerebral palsy-findings from prospective hospital-based surveillance in Vietnam indicate a need for action. Nutrients. (2019) 11(9):21–32. 10.3390/nu11092132

  • 43.

    Aneja S Ahuja B Taluja V Bhatia VK . Epilepsy in children with cerebral palsy. Indian J Pediatr. (2001) 68(2):111–5. 10.1007/BF02722024

  • 44.

    Nordmark E Hägglund G Lagergren J . Cerebral palsy in southern Sweden I. Prevalence and clinical features. Acta Paediatr. (2001) 90(11):1271–6. 10.1080/080352501317130317

  • 45.

    Parkes J Dolk H Hill N Pattenden S . Cerebral palsy in northern Ireland: 1981–93. Paediatr Perinat Epidemiol. (2001) 15(3):278–86. 10.1046/j.1365-3016.2001.00349.x

  • 46.

    Carlsson M Hagberg G Olsson I . Clinical and aetiological aspects of epilepsy in children with cerebral palsy. Dev Med Child Neurol. (2003) 45(6):371–6. 10.1017/s0012162203000719

  • 47.

    El-Tallawy HN Farghaly WM Shehata GA Badry R Rageh TA . Epileptic and cognitive changes in children with cerebral palsy: an Egyptian study. Neuropsychiatr Dis Treat. (2014) 10:971–5. 10.2147/NDT.S59600

  • 48.

    Beckung E Hagberg G . Neuroimpairments, activity limitations, and participation restrictions in children with cerebral palsy. Dev Med Child Neurol. (2002) 44(5):309–16. 10.1017/s0012162201002134

  • 49.

    Andersen GL Irgens LM Haagaas I Skranes JS Meberg AE Vik T . Cerebral palsy in Norway: prevalence, subtypes and severity. Eur J Paediatr Neurol. (2008) 12(1):4–13. 10.1016/j.ejpn.2007.05.001

  • 50.

    Sigurdardóttir S Thórkelsson T Halldórsdóttir M Thorarensen O Vik T . Trends in prevalence and characteristics of cerebral palsy among Icelandic children born 1990 to 2003. Dev Med Child Neurol. (2009) 51(5):356–63. 10.1111/j.1469-8749.2009.03303.x

  • 51.

    Kirby RS Wingate MS Van Naarden Braun K Doernberg NS Arneson CL Benedict RE et al Prevalence and functioning of children with cerebral palsy in four areas of the United States in 2006: a report from the autism and developmental disabilities monitoring network. Res Dev Disabil. (2011) 32(2):462–9. 10.1016/j.ridd.2010.12.042

  • 52.

    Himmelmann K Uvebrant P . Function and neuroimaging in cerebral palsy: a population-based study. Dev Med Child Neurol. (2011) 53(6):516–21. 10.1111/j.1469-8749.2011.03932.x

  • 53.

    Sellier E Uldall P Calado E Sigurdardottir S Torrioli MG Platt MJ et al Epilepsy and cerebral palsy: characteristics and trends in children born in 1976-1998. Eur J Paediatr Neurol. (2012) 16(1):48–55. 10.1016/j.ejpn.2011.10.003

  • 54.

    Singhi P Saini AG . Changes in the clinical spectrum of cerebral palsy over two decades in north India–an analysis of 1212 cases. J Trop Pediatr. (2013) 59(6):434–40. 10.1093/tropej/fmt035

  • 55.

    Christensen D Van Naarden Braun K Doernberg NS Maenner MJ Arneson CL Durkin MS et al Prevalence of cerebral palsy, co-occurring autism spectrum disorders, and motor functioning—autism and developmental disabilities monitoring network, USA, 2008. Dev Med Child Neurol. (2014) 56(1):59–65. 10.1111/dmcn.12268

  • 56.

    Yalcinkaya EY Huner B Dincer U Diracoglu D Aydin R Icagasioglu A et al . Demographic and clinical findings of cerebral palsy patients in Istanbul: a multicenter study. Türkiye Fiziksel Tip ve Rehabilitasyon Dergisi. (2014) 60(2):134–8. 10.5152/tftrd.2014.42402

  • 57.

    Granild-Jensen JB Rackauskaite G Flachs EM Uldall P . Predictors for early diagnosis of cerebral palsy from national registry data. Dev Med Child Neurol. (2015) 57(10):931–5. 10.1111/dmcn.12760

  • 58.

    Meehan E Freed GL Reid SM Williams K Sewell JR Rawicki B et al Tertiary paediatric hospital admissions in children and young people with cerebral palsy. Child Care Health Dev. (2015) 41(6):928–37. 10.1111/cch.12263

  • 59.

    Delacy MJ Reid SM , Australian Cerebral Palsy Register Group. Profile of associated impairments at age 5 years in Australia by cerebral palsy subtype and gross motor function classification system level for birth years 1996 to 2005. Dev Med Child Neurol. (2016) 58(Suppl 2):50–6. 10.1111/dmcn.13012

  • 60.

    Tan SS van der Slot WM Ketelaar M Becher JG Dallmeijer AJ Smits DW et al Factors contributing to the longitudinal development of social participation in individuals with cerebral palsy. Res Dev Disabil. (2016) 57:125–35. 10.1016/j.ridd.2016.03.015

  • 61.

    Khandaker G Smithers-Sheedy H Islam J Alam M Jung J Novak I et al Bangladesh Cerebral Palsy Register (BCPR): a pilot study to develop a national cerebral palsy (CP) register with surveillance of children for CP. BMC Neurol. (2015) 15:173. 10.1186/s12883-015-0427-9

  • 62.

    Delobel-Ayoub M Klapouszczak D van Bakel MME Horridge K Sigurdardottir S Himmelmann K et al Prevalence and characteristics of autism spectrum disorders in children with cerebral palsy. Dev Med Child Neurol. (2017) 59(7):738–42. 10.1111/dmcn.13436

  • 63.

    Abas O Abdelaziem F Kilany A . Clinical spectrum of cerebral palsy and associated disability in south Egypt: a local survey study. Open Access Maced J Med Sci. (2017) 5(1):37–41. 10.3889/oamjms.2017.020

  • 64.

    Kakooza-Mwesige A Andrews C Peterson S Wabwire Mangen F Eliasson AC Forssberg H . Prevalence of cerebral palsy in Uganda: a population-based study. Lancet Glob Health. (2017) 5(12):e1275–82. 10.1016/S2214-109X(17)30374-1

  • 65.

    Yim SY Yang CY Park JH Kim MY Shin YB Kang EY et al Society of pediatric rehabilitation and developmental medicine, Korea. Korean database of cerebral palsy: a report on characteristics of cerebral palsy in South Korea. Ann Rehabil Med. (2017) 41(4):638–49. 10.5535/arm.2017.41.4.638

  • 66.

    Hollung SJ Vik T Lydersen S Bakken IJ Andersen GL . Decreasing prevalence and severity of cerebral palsy in Norway among children born 1999 to 2010 concomitant with improvements in perinatal health. Eur J Paediatr Neurol. (2018) 22(5):814–21. 10.1016/j.ejpn.2018.05.001

  • 67.

    Reid SM Meehan EM Arnup SJ Reddihough DS . Intellectual disability in cerebral palsy: a population-based retrospective study. Dev Med Child Neurol. (2018) 60(7):687–94. 10.1111/dmcn.13773

  • 68.

    Chiang KL Kuo FC Cheng CY Chang KP . Prevalence and demographic characteristics of comorbid epilepsy in children and adolescents with cerebral palsy: a nationwide population-based study. Childs Nerv Syst. (2019) 35(1):149–56. 10.1007/s00381-018-3920-9

  • 69.

    Jonsson U Eek MN Sunnerhagen KS Himmelmann K . Cerebral palsy prevalence, subtypes, and associated impairments: a population-based comparison study of adults and children. Dev Med Child Neurol. (2019) 61(10):1162–7. 10.1111/dmcn.14229

  • 70.

    Khandaker G Muhit M Karim T Smithers-Sheedy H Novak I Jones C et al Epidemiology of cerebral palsy in Bangladesh: a population-based surveillance study. Dev Med Child Neurol. (2019) 61(5):601–9. 10.1111/dmcn.14013

  • 71.

    Påhlman M Gillberg C Himmelmann K . One-third of school-aged children with cerebral palsy have neuropsychiatric impairments in a population-based study. Acta Paediatr. (2019) 108(11):2048–55. 10.1111/apa.14844

  • 72.

    Andrews C Kakooza-Mwesige A Almeida R Swartling Peterson S Wabwire-Mangen F Eliasson AC et al Impairments, functional limitations, and access to services and education for children with cerebral palsy in Uganda: a population-based study. Dev Med Child Neurol. (2020) 62(4):454–62. 10.1111/dmcn.14401

  • 73.

    Rafique A Naz H . A survey-based report on the occurrence of cerebral palsy in Urban areas of Karachi. J Pak Med Assoc. (2020) 70(8):1442–4. 10.5455/JPMA.28135

  • 74.

    Jahan I Al Imam MH Karim T Muhit M Hardianto D Das MC et al Epidemiology of cerebral palsy in Sumba Island, Indonesia. Dev Med Child Neurol. (2020) 62(12):1414–22. 10.1111/dmcn.14616

  • 75.

    Hollung SJ Bakken IJ Vik T Lydersen S Wiik R Aaberg KM et al Comorbidities in cerebral palsy: a patient registry study. Dev Med Child Neurol. (2020) 62(1):97–103. 10.1111/dmcn.14307

  • 76.

    Yamagishi H Osaka H Toyokawa S Kobayashi Y Shimoizumi H . Survey on children with cerebral palsy in tochigi prefecture, Japan. Pediatr Int. (2021) 63(8):951–7. 10.1111/ped.14536

  • 77.

    Duke RE Torty C Okorie U Kim MJ Eneli N Edadi U et al Pattern of comorbidities in school-aged children with cerebral palsy in cross river state, Nigeria. BMC Pediatr. (2021) 21(1):165. 10.1186/s12887-021-02637-9

  • 78.

    Al-Garni S Derbala S Saad H Maaty AI . Developmental anomalies and associated impairments in Saudi children with cerebral palsy: a registry-based, multicenter study. Egyptian Rheumatology and Rehabilitation. (2021) 48(1):1–9. 10.1186/s43166-021-00057-2

  • 79.

    Bambi EN Mwesige AK Lekuya HM Kasirye P Idro R . Chronic pain among children with cerebral palsy attending a Ugandan tertiary hospital: a cross-sectional study. BMC Pediatr. (2021) 21(1):456. 10.1186/s12887-021-02928-1

  • 80.

    Karim T Das MC Muhit M Badawi N Khandaker G Mohammad SS . Improving epilepsy control among children with cerebral palsy in rural Bangladesh: a prospective cohort-based study. BMJ Open. (2022) 12(4):e052578. 10.1136/bmjopen-2021-052578

  • 81.

    Szpindel A Myers KA Ng P Dorais M Koclas L Pigeon N et al Epilepsy in children with cerebral palsy: a data linkage study. Dev Med Child Neurol. (2022) 64(2):259–65. 10.1111/dmcn.15028

  • 82.

    Linton G Hägglund G Czuba T Alriksson-Schmidt AI . Epidemiology of fractures in children with cerebral palsy: a Swedish population-based registry study. BMC Musculoskelet Disord. (2022) 23(1):862. 10.1186/s12891-022-05813-9

  • 83.

    Paget S Ostojic K Goldsmith S Nassar N McIntyre S . Determinants of hospital-based health service utilization in cerebral palsy: a systematic review. Arch Phys Med Rehabil. (2022) 103(8):1628–37. 10.1016/j.apmr.2021.12.003

  • 84.

    Leite HR Jindal P Malek SA Rosenbaum P . Research on children with cerebral palsy in low- and middle-income countries. Pediatr Phys Ther. (2022) 34(4):551–5. 10.1097/PEP.0000000000000949

  • 85.

    Sogbossi ES Houekpetodji D Kpadonou TG Bleyenheuft Y . Mothers’ perception of cerebral palsy in a low-income country of West Africa: a cross-sectional study. Disabil Rehabil. (2022) 44(17):4767–74. 10.1080/09638288.2021.1919765

  • 86.

    Novak I Morgan C Adde L Blackman J Boyd RN Brunstrom-Hernandez J et al Early, accurate diagnosis and early intervention in cerebral palsy: advances in diagnosis and treatment. JAMA Pediatr. (2017) 171(9):897–907; Erratum in: JAMA Pediatr. 2017 Sep 1;171(9):919. 10.1001/jamapediatrics.2017.1689

  • 87.

    Karim T Dossetor R Huong Giang NT Dung TQ Son TV Hoa NX et al Data on cerebral palsy in Vietnam will inform clinical practice and policy in low and middle-income countries. Disabil Rehabil. (2022) 44(13):3081–8. 10.1080/09638288.2020.1854872

  • 88.

    Levene M . The clinical conundrum of neonatal seizures. Arch Dis Child Fetal Neonatal Ed. (2002) 86:F75–7. 10.1136/fn.86.2.f75

  • 89.

    Jan MMS . Cerebral palsy: comprehensive review and update. Ann Saudi Med. (2006) 26(2):123–32. 10.5144/0256-4947.2006.123

  • 90.

    Fluss J Lidzba K . Cognitive and academic profiles in children with cerebral palsy: a narrative review. Ann Phys Rehabil Med. (2020) 63(5):447–56. 10.1016/j.rehab.2020.01.005

  • 91.

    Scheffer IE Berkovic S Meletti S Connolly MB French J Guilhoto L et al ILAE Classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. (2017) 58:512–21. 10.1111/epi.13709

  • 92.

    Ogoke CC . Clinical classification of cerebral palsy. In: Clinical and therapeutic aspects. (2018). p. 21. 10.5772/intechopen.79246

  • 93.

    Krägeloh-Mann I Horber V . The role of magnetic resonance imaging in elucidating the pathogenesis of cerebral palsy: a systematic review. Dev Med Child Neurol. (2007) 49(2):144–51. 10.1111/j.1469-8749.2007.00144.x

  • 94.

    Shevell MI Majnemer A Morin I . Etiologic yield of cerebral palsy: a contemporary case series. Pediatr Neurol. (2003) 28(5):352–9. 10.1016/s0887-8994(03)00006-7

  • 95.

    Wallace SJ . Epilepsy in cerebral palsy. Dev Med Child Neurol. (2001) 43(10):713–7. 10.1017/s0012162201001281

  • 96.

    Towsley K Shevell MI Dagenais L . REPACQ Consortium. Population-based study of neuroimaging findings in children with cerebral palsy. Eur J Paediatr Neurol. (2011) 15(1):29–35. 10.1016/j.ejpn.2010.07.005

  • 97.

    Patsopoulos NA Evangelou E Ioannidis JP . Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol. (2008) 37(5):1148–57. 10.1093/ije/dyn065

Summary

Keywords

cerebral palsy, epilepsy, prevalence, children, meta-analyses

Citation

Gong C, Liu A, Lian B, Wu X, Zeng P, Hao C, Wang B, Jiang Z, Pang W, Guo J and Zhou S (2023) Prevalence and related factors of epilepsy in children and adolescents with cerebral palsy: a systematic review and meta-analysis. Front. Pediatr. 11:1189648. doi: 10.3389/fped.2023.1189648

Received

19 March 2023

Accepted

10 July 2023

Published

28 July 2023

Volume

11 - 2023

Edited by

Pasquale Parisi, Sapienza University of Rome, Italy

Reviewed by

Kuo-Liang Chiang, Kuang Tien General Hospital, Taiwan Orawan Keeratisiroj, Naresuan University, Thailand

Updates

Copyright

* Correspondence: Jin Guo Shaobo Zhou

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics